Organogenesis Announces Arthritis Trial Results At Meeting.
CANTON, Mass., March 12, 2019 -- Organogenesis Holdings Inc. (NASDAQ: ORGO) announced that clinical trial results demonstrating the effectiveness of its amniotic fluid-derived allograft in treating symptoms associated with knee osteoarthritis (OA) were presented at the American Academy of Orthopedic Surgeons annual meeting last month in Las Vegas.
About 30.8 million Americans--13.4 percent of the U.S. adult population--have been diagnosed with osteoarthritis, with the knee being one of the most commonly affected areas.
More than half of all people with knee OA are younger than 65 and may live for decades after their diagnosis, substantially increasing the time for disability to occur.
While there is no known treatment that completely cures knee OA, it is possible to treat disease symptoms with the goal of avoiding or delaying costly and invasive knee replacement surgery.
ReNu is a cryopreserved, amniotic suspension allograft, derived from human amnion and amniotic fluid.
The human amniotic tissues in ReNu contain cellular components, growth factors, and extracellular matrix, and are naturally rich in anti-inflammatory growth factors.
ReNu is manufactured by Organogenesis.
|Printer friendly Cite/link Email Feedback|
|Publication:||Stem Cell Research News|
|Date:||Apr 22, 2019|
|Previous Article:||Promethera Biosciences To Present Data From Trial In Liver Failure.|
|Next Article:||Cells Within Cancer Stem Cells Appear To Signal How Surrounding Cells Will Grow.|